Lenvatinib
- Generic Name
- Lenvatinib
- Brand Names
- Lenvima 10, Kisplyx, Lenvima
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClN4O4
- CAS Number
- 417716-92-8
- Unique Ingredient Identifier
- EE083865G2
- Background
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...
- Indication
Lenvatinib is indicated for the treatment of the following cancerous conditions:
Differentiated Thyroid Cancer (DTC)
Renal Cell Carcinoma (RCC)
Hepatocellular Carcinoma (HCC)
Endometrial Carcinoma
- Associated Conditions
- Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
- Associated Therapies
- -
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Tel Aviv Medical Center
- Target Recruit Count
- 47
- Registration Number
- NCT05973903
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 30
- Registration Number
- NCT05949424
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
Pembrolizumab in Combination With Lenvatinib in Pts With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 42
- Registration Number
- NCT05903833
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05903456
Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 25
- Registration Number
- NCT05901194
- Locations
- 🇫🇷
Hospital Claude Huriez, Lille, France
🇫🇷Paul Brousse Hospital, Villejuif, France
🇫🇷Hospital Haut levêque, Bordeaux, France
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
- Conditions
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 249
- Registration Number
- NCT05899049
- Locations
- 🇨🇳
Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000), Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital ( Site 6009), Chongqing, Chongqing, China
🇨🇳SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003), Guangzhou, Guangdong, China
Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05897268
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)
- Conditions
- Interventions
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05893056
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 200
- Registration Number
- NCT05889949
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05877820
- Locations
- 🇨🇳
Ethics Committee of Shanghai Renji Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.